New cancer clinical trial: Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Published on: April 26, 2018 at 12:00PM
Conditions:   Ovarian Neoplasm Epithelial;   High Grade Serous Carcinoma
Intervention:   Drug: Pegylated liposomal doxorubicin plus Bortezomib
Sponsor:   Seoul National University Hospital
Not yet recruiting
https://ift.tt/2HWv3uH